TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02075502

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lower extremity ET
Description: catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
Study: NCT04576455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT00750386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, I.V, every 2 weeks
Study: NCT04576455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Agonist
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT04862403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping distance
Description: Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping distance
Description: Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
Study: NCT02748798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 3He
Description: 3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 3He
Description: 3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 129Xe
Description: 129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP 129Xe
Description: 129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Study: NCT00750386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC, I.V, 5 every 2 weeks
Study: NCT02075502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower extremity ET
Description: catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: peripheral open intervention
Description: revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral open intervention
Description: revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
Study: NCT04893746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10-L
Description: Low dose: 2x1010 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 0x1010 CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10-H
Description: High dose: 6x1010 CFU/day
Study: NCT03958682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR smart wearing equipment combined with 4G + satellite information transmission system
Description: We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors.
Study: NCT06207500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led Medication Reconciliation
Description: The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
Study: NCT03052608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK-positive NSCL treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: ALK-positive NSCL treatment
Study: NCT02748798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF6
Description: Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF6
Description: Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 129Xe Small and Large Human Lung Coil
Description: The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 129Xe Small and Large Human Lung Coil
Description: The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3He Human Lung Coil
Description: The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3He Human Lung Coil
Description: The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
Study: NCT03071159

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Flash Libre glucose monitoring system
Description: glucose monitoring system with sensors
Study: NCT00520832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: 20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
Study: NCT02748798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFP and SF6 Human Lung Coil
Description: The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFP and SF6 Human Lung Coil
Description: The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
Study: NCT01933152

Intervention type: DRUG
Intervention: Ranibizumab
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Study: NCT02522221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin is an oral vitamin K antagonist anticoagulant.
Study: NCT02647762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 1 mg
Description: CF101 tablets, 1mg BID for 12 weeks
Study: NCT02522221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tecarfarin
Description: Tecarfarin is an oral vitamin K antagonist anticoagulant
Study: NCT01321580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Pronto 7
Description: non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
Study: NCT02647762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2 mg
Description: CF101 tablets, 2 mg BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 1mg BID for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
Study: NCT01808118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every other week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every other week
Study: NCT04420871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg of Xeloda®
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg of capecitabine
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
Study: NCT03940651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Patients will be randomized to type of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Patients will be randomized to type of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthetics
Description: Patients will be randomized to type of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthetics
Description: Patients will be randomized to type of anesthesia
Study: NCT01701583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
Study: NCT03218852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone and cyclophosphamide
Description: Prednisone and cyclophosphamide are both administered to participants in this group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone alone
Description: Prednisone is administered to participants in this group.
Study: NCT03712163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 1)
Description: Single dose Norketotifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 2)
Description: Single dose Norketotifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 3)
Description: Single dose Norketotifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Multiple Dose Cohort)
Description: Multiple dose Norketotifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo
Study: NCT02679274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intermittent intramuscular injections of saline (males and females).
Study: NCT03712163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo
Study: NCT02306772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating A
Description: One radio-labelled tablet given to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating B
Description: One radio-labelled tablet given to subjects
Study: NCT04116632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Single dose with varying frequency among groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Single dose with varying frequency among groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Single dose with varying frequency among groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02679274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
Study: NCT03757663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UV Counseling
Description: Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
Study: NCT01734122

Intervention type: OTHER
Intervention: Questionnaires / Observational Assessments
Description: Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation

Intervention type: OTHER
Intervention: Questionnaires / Observational Assessments
Description: Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
Study: NCT04116632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00530322

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy).

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy).
Study: NCT00905879

Intervention type: DRUG
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
Study: NCT01222338

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V-5 immunitor
Description: once per day dosing for 2 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V-5 immunitor
Description: once per day dosing for 2 months
Study: NCT00589888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20% @ 20cc/hour
Description: In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%@ 40cc/hour
Description: In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 32-gram oral fat load
Description: In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 64-gram oral fat load
Description: In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
Study: NCT03089177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Garden Intervention
Description: The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year.
Study: NCT01143350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bras A (EHPAD Training and stimulation)
Description: EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EHPAD Control
Description: EHPAD of the reference group, will have their habitual functioning
Study: NCT03175393

Intervention type: DEVICE
Intervention: coronary angiography
Description: per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score